Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 2(2)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06125028Phase 3Terminated

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Role: lead

NCT05222269Phase 2Terminated

[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients

Role: lead

NCT06132737Phase 1Recruiting

[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients

Role: lead

NCT06478875Phase 2Not Yet Recruiting

Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism

Role: collaborator

All 4 trials loaded